30,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
We suggest that 6 months of dietary n-3 FA supplementation affected expression of genes that might influence inflammatory processes and could be of significance for AD. 3 key findings →
Participants: 16 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Cerebrovascular changes, including reduced cerebral blood flow (CBF), occur early in the development of Alzheimer disease and may accelerate disease progression. 3 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
In this randomized clinical trial, rotigotine treatment did not significantly affect global cognition in patients with mild to moderate AD; however, improvement was observed in cognitive functions highly associated with the frontal lobe and in activities of daily living. 5 key findings →
Design: longitudinal study Participants: 47 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Early intervention to reduce caregiving behavioral burden and enhance family support and promote healthier behaviors of bereaved AD caregivers may decrease the risk of syndromal or syndromal-becoming-threshold level depression after loss. 3 key findings →
Participants: 30 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The GuidAge study is the largest study carried out in Europe on the prevention of AD. 2 key findings →
Design: randomized controlled trial Participants: 2,854 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Disclosure of pleiotropic information did not increase anxiety or depression and may have decreased distress among persons at increased risk for 2 conditions. 2 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
After 3 months, IG improved gait speed (p = 0.016), implying a statistically significant difference between groups in favour of IG (p = 0.003). 3 key findings →
Design: randomized controlled trial Participants: 31 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
There were no statistical differences between the placebo or solanezumab groups in CDR-G, CDR-SB, specific CDR boxes or CDR composite scores over the course of the trial. 3 key findings →
Participants: 583 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Among 137 randomized participants, 2 were excluded for not meeting eligibility criteria, leaving 135 (mean [SD] age, 69.3 [3.8] years; 83 female [61%]) eligible for analysis. 3 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Based on the hypothesis of glutamate-induced neurotoxicity (excitotoxicity) in cerebral ischemia, this study examined the efficacy and tolerability of memantine, an uncompetitive N-methyl-D-aspartate antagonist, in the treatment of mild to moderate vascular dementia. 4 key findings →
Participants: 321 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The aim of the reported trial was to investigate the safety and efficacy of memantine in mild to moderate vascular dementia (VaD). 4 key findings →
Design: randomized controlled trial Participants: 579 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The long-term efficacy and safety of donepezil (up to 10 mg/day) was evaluated in a multicentre, non-randomised, open-label extension study of 133 patients with mild to moderate Alzheimer's disease (AD) who had completed a previous 14-week double-blind, placebo-controlled trial of donepezil. 4 key findings →
Design: open-label trial Participants: 133 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
We aimed to determine prospectively whether rivastigmine, an inhibitor of acetylcholinesterase and butyrylcholinesterase, provided benefits in patients with and without visual hallucinations in a population with dementia associated with Parkinson's disease (PDD). 4 key findings →
Participants: 188 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Patients with Alzheimer dementia from the Swedish Dementia Registry starting on ChEIs within 3 months of the dementia diagnosis were included and compared to nontreated patients with Alzheimer dementia. 4 key findings →
Participants: 11,652 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Nonlinear dose-response relationship between exercise and cognitive improvement in Alzheimer's disease, with the optimal AE dose identified at 660 METs-min/week for enhancing cognitive function in AD. 3 key findings →
Design: meta-analysis Participants: 2,242 Evidence: early
Full summary, score breakdown and related studies → Original source Free full text
Our findings illuminate the potential benefits of ChEI treatment in DLB patients. 4 key findings →
Design: cohort Participants: 1,095 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Counseling and support preserved SRH in vulnerable caregivers. 2 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Sodium benzoate substantially improved cognitive and overall functions in patients with early-phase AD. 3 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Individuals with Down syndrome over age 40 years are at risk for developing dementia of the Alzheimer type and have evidence for chronic oxidative stress. 4 key findings →
Participants: 53 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
After removal of duplicates, our initial search returned 3955 records. 3 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
This multicenter trial showed no benefit of divalproex sodium for treatment for agitation in dementia at a mean dose of 800 mg/day over 6 weeks. 3 key findings →
Participants: 75 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
In nursing home residents with AD and psychosis, aripiprazole did not confer specific benefits for the treatment of psychotic symptoms; but psychological and behavioral symptoms, including agitation, anxiety, and depression, were improved with aripiprazole, with a low risk of AEs. 4 key findings →
Participants: 131 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Finding positive gains is an effective intervention to reduce depressive symptoms among Alzheimer caregivers. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
We found no benefit to low-flow CSF shunting in subjects with mild to severe Alzheimer disease. 4 key findings →
Design: longitudinal study Participants: 215 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Efficacy analysis included 416 patients. 3 key findings →
Participants: 238 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 30,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 30,180 records, built mostly from automated pulls of Europe PMC (64.2% of the library) and OpenAlex (16.9%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,037 records (3.4% of the library) are not peer-reviewed — 964 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →